At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SD Sandridge Energy Inc.
Market Closed 10-23 16:00:00 EDT
14.76
+0.52
+3.65%
盘后14.76
+0.000.00%
19:30 EDT
High14.80Low14.24Vol281.41K
Open14.26D1 Closing14.24Amplitude3.97%
Mkt Cap547.23MTradable Cap536.61MTotal Shares37.08M
T/O4.13MT/O Rate0.77%Tradable Shares36.36M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
GlobeNewswire  ·  10-23 23:45
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
GlobeNewswire  ·  10-23 21:15
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
GlobeNewswire  ·  10-12
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
GlobeNewswire  ·  10-07
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
GlobeNewswire  ·  09-30
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Jakarta Shifts to Remote Learning over Anak Krakatau Ash
Tempo  ·  09-06
Jakarta Shifts to Remote Learning over Anak Krakatau Ash
Create SD Holdings Details Controlling Shareholder Structure and Minority Protection Measures
TIPRANKS  ·  08-24
Create SD Holdings Details Controlling Shareholder Structure and Minority Protection Measures
SD Guthrie's 2H Earnings Likely to be Flattish
Dow Jones  ·  08-12
SD Guthrie's 2H Earnings Likely to be Flattish
Mach Natural Resources Q2 Adjusted Ebitda Slightly Misses Estimates
Reuters  ·  08-07
Mach Natural Resources Q2 Adjusted Ebitda Slightly Misses Estimates
SandRidge Energy Declares $0.13-a-Share Dividend
Reuters  ·  08-06
SandRidge Energy Declares $0.13-a-Share Dividend
SandRidge Energy Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
SandRidge Energy Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
SandRidge Energy Q2 Revenue Rises 48% on Higher Output and Prices
Reuters  ·  08-06
SandRidge Energy Q2 Revenue Rises 48% on Higher Output and Prices
SandRidge Energy Q2 Adj. EPS $0.57 Misses $0.75 Estimate, Sales $51.117M Miss $58.700M Estimate
Benzinga Earnings  ·  08-06
SandRidge Energy Q2 Adj. EPS $0.57 Misses $0.75 Estimate, Sales $51.117M Miss $58.700M Estimate
SandRidge Energy Q2 EPS USD 0.72
THOMSON REUTERS  ·  08-06
SandRidge Energy Q2 EPS USD 0.72
SandRidge Energy Q2 Adjusted Net Income USD 21 Million
THOMSON REUTERS  ·  08-06
SandRidge Energy Q2 Adjusted Net Income USD 21 Million
SandRidge Energy, Inc. Announces Financial and Operating Results for the Three and Six-Month Periods Ended June 30, 2026 and Declares Dividend of $0.13 Per Share
THOMSON REUTERS  ·  08-06
SandRidge Energy, Inc. Announces Financial and Operating Results for the Three and Six-Month Periods Ended June 30, 2026 and Declares Dividend of $0.13 Per Share
SandRidge Energy Updates Financial Calendar with Q2 Results Release, Conference Call
Reuters  ·  08-04
SandRidge Energy Updates Financial Calendar with Q2 Results Release, Conference Call
SandRidge Energy Inc Expected to Post Earnings of 75 Cents a Share - Earnings Preview
Reuters  ·  08-01
SandRidge Energy Inc Expected to Post Earnings of 75 Cents a Share - Earnings Preview
SD Guthrie, Sime Darby Property to Pay MYR798 Million for Selangor Land
MT Newswires Live  ·  07-16
SD Guthrie, Sime Darby Property to Pay MYR798 Million for Selangor Land
SD Guthrie's Land Sale Could Boost Earnings
Dow Jones  ·  07-16
SD Guthrie's Land Sale Could Boost Earnings

Introduction

Company Name.
Sandridge Energy Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
SandRidge Energy, Inc. engages in the acquisition, development, and production of oil and natural gas primarily in the United States Mid-Continent. As of December 31, 2022, it had an interest in 1,471 gross producing wells. The company was incorporated in 2006 and is headquartered in Oklahoma City, Oklahoma.
Issue price:
--